Efficacy of atezolizumab in patients resistant to platinum-based chemotherapy. Results of the AURORA-RU Study: Atezolizumab in UROthelial cancer: Real-world Analysis of RUssia

Evgeniy A. Usynin; Усынин Евгений Анатольевич; O. V. Leonov; Леонов О. В.; E. I. Kopyltsov; Копыльцов Е. И.; S. A. Fursov; Фурсов С. А.; E. A. Bukhonin; Бухонин Е. А.; R. A. Zukov; Зуков Р. А.; Yu. V. Anzhiganova; Анжиганова Ю. В.; D. D. Kadyrova; Кадырова Д. Д.; M. A. Zafirova; Зафирова М. А.; I. Yu. Ali; Али И. Ю.; V. N. Zakharov; Захаров В. Н.; A. V. Sobolev; Соболев А. В.; N. P. Modin; Модин Н. П.; A. K. Gural; Гураль А. К.; Z. A. Yurmazov; Юрмазов З. А.; L. V. Sebyakina; Себякина Л. В.; M. Yu. Mostovoy; Мостовой М. Ю.; O. S. Tsirulnikova; Цирульникова О. С.; A. M. Degtyarev; Дегтярев А. М.; M. A. Yavorskaya; Яворская М. А.; N. A. Riger; Ригер Н. А.; G. A. Rafikova; Рафикова Г. А.; E. S. Vorobyeva; Воробьева Е. С.; V. V. Kuznetsova; Кузнецова В. В.; E. M. Anokhina; Анохина Е. М.; A. D. Murskikh; Мурских А. Д.; D. M. Dubovichenko; Дубовиченко Д. М.; V. V. Kurilkina; Курилкина В. В.; M. A. Oganyan; Оганян М. А.; V. S. Myagkova; Мягкова В. С.; V. S. Bobrov; Бобров В. С.

doi:10.17650/1726-9776-2025-21-4-76-87

Efficacy of atezolizumab in patients resistant to platinum-based chemotherapy. Results of the AURORA-RU Study: Atezolizumab in UROthelial cancer: Real-world Analysis of RUssia

Authors: Usynin E.A.¹, Leonov O.V.²^,3, Kopyltsov E.I.², Fursov S.A.⁴^,5, Bukhonin E.A.⁵, Zukov R.A.⁶^,7, Anzhiganova Y.V.⁶, Kadyrova D.D.⁶, Zafirova M.A.⁸, Ali I.Y.⁸, Zakharov V.N.⁹^,10, Sobolev A.V.⁹, Modin N.P.⁹^,10, Gural A.K.¹¹, Yurmazov Z.A.¹, Sebyakina L.V.¹², Mostovoy M.Y.¹³, Tsirulnikova O.S.¹³, Degtyarev A.M.¹⁴, Yavorskaya M.A.¹⁴, Riger N.A.¹⁴, Rafikova G.A.¹⁴, Vorobyeva E.S.¹⁴, Kuznetsova V.V.¹⁴, Anokhina E.M.¹⁵, Murskikh A.D.¹⁵, Dubovichenko D.M.¹⁶, Kurilkina V.V.¹⁷, Oganyan M.A.¹⁷, Myagkova V.S.¹⁸, Bobrov V.S.¹⁹
Affiliations:
1. Tomsk National Research Medical Center of the Russian Academy of Sciences
2. Clinical Oncology Dispensary, Omsk
3. Omsk State Medical University, Ministry of Health of Russia
4. Novosibirsk State Medical University, Ministry of Health of Russia
5. Novosibirsk Regional Clinical Oncology Dispensary
6. A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary
7. Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia
8. Sverdlovsk Regional Oncology Dispensary, Yekaterinburg
9. Kuzbass Clinical Oncology Dispensary named after M.S. Rappoport
10. Kemerovo State Medical University, Ministry of Health of Russia
11. Tomsk Regional Oncology Dispensary
12. Oncology Dispensary No. 3, Ministry of Health of the Krasnodar Territory, Novorossiysk
13. Clinical Oncology Dispensary No. 1, Ministry of Health of the Krasnodar Territory, Krasnodar
14. Oncology Dispensary No. 2, Ministry of Health of the Krasnodar Territory, Sochi
15. St. Luke Clinical Hospital
16. Arkhangelsk Clinical Oncology Dispensary
17. Clinical and Diagnostic Center “Zdorovye” in Rostov-on-Don
18. Rostov Regional Oncology Dispensary, Rostov-on-Don
19. National Medical Research Radiological Center, Ministry of Health of Russia
Issue: Vol 21, No 4 (2025)
Pages: 76-87
Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCER
Published: 27.02.2026
URL: https://oncourology.eco-vector.com/oncur/article/view/2025
DOI: https://doi.org/10.17650/1726-9776-2025-21-4-76-87
ID: 2025

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Background. The decade-long use of checkpoint inhibitors in real-world clinical practice in Russia allowed to treat hundreds of patients with urothelial malignancies. The AURORA-RU Phase IV observational Russian study was initiated to evaluate the efficacy of atezolizumab in patients with urothelial carcinoma resistant to platinum-based chemotherapy. This article is based on an analysis conducted at a median follow-up of 60.7 months and provides data on treatment efficacy in Russian patients receiving second-line and subsequent lines of systemic therapy.

Aim. To evaluate the clinical efficacy of atezolizumab monotherapy in patients with urothelial carcinoma of the upper and lower urinary tract progressing on platinum-based chemotherapy in a real-world clinical setting. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included subgroup analyses of efficacy based on the line of therapy (including the subgroup with early progression after neo/adjuvant chemotherapy [NACT/ACT]), age cohort, metastatic sites, and primary tumor location (bladder vs. upper urinary tract).

Materials and methods. The study included data from 152 patients with verified muscle-invasive locally advanced and metastatic urothelial carcinoma who received PD-L1 inhibitor (atezolizumab) monotherapy across 13 centers in the Russian Federation between 2019 and 2025. Atezolizumab treatment was administered to patients who progressed on platinum-based chemotherapy. More than half of the patients (55.9 %) were over 65 years of age. The cohort consisted of 75.0 % men and 25.0 % women. The majority of patients (78.3 %) had a primary tumor located in the bladder. PD-L1 inhibitor therapy was administered as second-line treatment in 57.9 % of cases, while one in five patients (21.7 %) received third-line treatment. In 86.8 % of cases, treatment was administered without prior assessment of PD-L1 expression levels.

Results. In the overall cohort, the median PFS reached 5.5 months, with 36-month and 48-month PFS rates of 15.9 % and 9.9 %, respectively. The median OS was 12.0 months; 21.9 % of patients survived 3 years, and 14.3 % of patients remained under observation for five years. In patients transitioning to immuno-oncology treatment after rapid progression following NACT/ACT, the median OS was 17.4 months. The median OS for second-line therapy was two-fold higher than for third-line therapy: 13.9 months versus 6.1 months. High treatment efficacy was noted in patients over 70 years of age (median PFS of 8.7 months; median OS of 14.9 months).

Conclusion. In real-world practice, PFS and OS rates were comparable to those reported in registration trials and other real-world evidence studies. The lack of PD-L1 expression testing generally did not affect the efficacy of immuno-oncology therapy in patients with urothelial carcinoma.

Keywords

urothelial carcinoma, atezolizumab, survival, real-world evidence study, phase IV study

About the authors

Evgeniy A. Usynin

Tomsk National Research Medical Center of the Russian Academy of Sciences

Author for correspondence.
Email: gusi70@list.ru
ORCID iD: 0000-0001-7127-0188

Cancer Research Institute

Russian Federation, 5 Cooperativny Pereulok, Tomsk 634009

Cancer Research Institute

Russian Federation, 5 Cooperativny Pereulok, Tomsk 634009

P.A. Hertzen Moscow Oncology Research Institute

Russian Federation, 3 2nd Botkinskiy Proezd, Moscow 125284

References

Bladder cancer. Clinical guidelines of the Ministry of Health of Russia, 2023. Available at: https://cr.minzdrav.gov.ru/view-cr/11_3 (accessed on 06.02.2026). (In Russ.).
Urothelial cancer of the upper urinary tract. Clinical guidelines of the Ministry of Health of Russia, 2023. Available at: https://cr.minzdrav.gov.ru/view-cr/526_2 (accessed on 06.02.2026). (In Russ.).
Usynin E.A., Gural A.K., Tashireva L.A. et al. Neoadjuvant combination drug therapy in treatment of patients with muscle-invasive bladder cancer. Onkourologiya = Cancer Urology 2025;21(3):124–9. (In Russ.). doi: 10.17650/1726-9776-2025-21-3-124-129
Powles T., Park S.H., Voog E. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383(13):1218–30. doi: 10.1056/NEJMoa2002788
Balar A.V., Galsky M.D., Rosenberg J.E. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389(10064):67–76. doi: 10.1016/S0140-6736(16)32455-2. Erratum in: Lancet 2017;390(10097):848. doi: 10.1016/S0140-6736(17)32213-4
Rosenberg J.E., Galsky M.D., Powles T. et al. Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial. ESMO Open 2024;9(12): 103972. doi: 10.1016/j.esmoop.2024.103972
Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. doi: 10.1056/NEJMoa1613683
Balar A.V., Castellano D., O’Donnell P.H. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18(11):1483–92. doi: 10.1016/S1470-2045(17)30616-2
Sharma P., Retz M., Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):312–22. doi: 10.1016/S1470-2045(17)30065-7
Sharma P., Callahan M.K., Bono P. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016;17(11):1590–8. doi: 10.1016/S1470-2045(16)30496-X
Bamias A., Davis I.D., Galsky M.D. et al. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. Lancet Oncol 2024;25(1):46–61. doi: 10.1016/S1470-2045(23)00539-9
Powles T., van der Heijden M.S., Castellano D. et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2020;21(12):1574–88. doi: 10.1016/S1470-2045(20)30541-6. Erratum in: Lancet Oncol 2021;22(1):e5. doi: 10.1016/S1470-2045(20)30734-8
Perez-Gracia J.L., Loriot Y., Rosenberg J.E. et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: outcomes by prior number of regimens. Eur Urol 2018;73(3):462–8. doi: 10.1016/j.eururo.2017.11.023. Erratum in: Eur Urol 2019;75(3):e82–3. doi: 10.1016/j.eururo.2018.11.032
Freites-Martinez A., Santana N., Arias-Santiago S., Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE – Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr 2021;112(1):90–2. doi: 10.1016/j.ad.2019.05.00911
Van der Heijden M.S., Loriot Y., Durán I. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma: a long-term overall survival and safety update from the phase 3 IMvigor211 clinical trial. Eur Urol 2021;80(1):7–11. doi: 10.1016/j.eururo.2021.03.024
Inman B.A., Longo T.A., Ramalingam S., Harrison M.R. Atezolizumab: a PD-L1-blocking antibody for bladder cancer. Clin Cancer Res 2017;23(8):1886–90. doi: 10.1158/1078-0432.CCR-16-1417
Sternberg C.N., Loriot Y., Choy E. et al. Final results from SAUL, a single-arm international study of atezolizumab in unselected patients with pretreated locally advanced/metastatic urinary tract carcinoma. Eur Urol Focus 2024;10(6):938–46. doi: 10.1016/j.euf.2024.05.007
Girard N., Popat S., Shoshkova S. et al. Effectiveness and safety data from IMreal cohort 1: patients (pts) with urothelial cancer (UC) receiving atezolizumab after platinum-containing chemotherapy (plt chemo) under real-world conditions. Immun Oncol Technol 2022. doi: 10.1016/j.iotech.2022.100179
Díaz Acedo R., Galvan Banqueri M., Artacho Criado S. et al. Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer. Int J Clin Pharm 2024;46(2):382–9. doi: 10.1007/s11096-023-01667-w
Tural D., Ölmez Ö.F., Sümbül A.T. et al. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: results of real-life experiences. Eur Urol Focus 2021;7(5):1061–6. doi: 10.1016/j.euf.2020.09.010

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register